Sistema de Salut de Catalunya
Institut Català de la Salut
[Saini KS] Fortrea Inc., Durham, NC, United States. Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom. [Somara S, Thatai P] Fortrea Inc., Durham, NC, United States. [Ko HC, Wallen ZD] Labcorp Oncology, Durham, NC, United States. [Quintana A] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2024-12-04T08:44:44Z
2024-12-04T08:44:44Z
2024-10-08
Diagnostic biomarker; Head and neck cancer; Squamous cell cancer
Biomarcador diagnóstico; Cáncer de cabeza y cuello; Cáncer de células escamosas
Biomarcador diagnòstic; Càncer de cap i coll; Càncer de cèl·lules escamoses
Recent strides in understanding the molecular underpinnings of head and neck cancers have sparked considerable interest in identifying precise biomarkers that can enhance prognostication and enable personalized treatment strategies. Immunotherapy has particularly revolutionized the therapeutic landscape for head and neck squamous cell carcinoma, offering new avenues for treatment. This review comprehensively examines the application and limitations of the established and emerging/novel biomarkers for head and neck squamous cell carcinoma. Established biomarkers, including well-characterized genetic mutations, protein expressions, and clinical factors, have been extensively studied and validated in clinical practice. Novel biomarkers identified through molecular analyses, including novel genetic alterations, immune-related markers, and molecular signatures, are currently being investigated and validated in preclinical and clinical settings. Biomarkers hold the potential to deepen our understanding of head and neck squamous cell carcinoma biology and guide therapeutic strategies. The evolving paradigm of predictive biomarkers facilitates the study of individual responses to specific treatments, including targeted therapy and immunotherapy.
Article
Versió publicada
Anglès
Marcadors tumorals; Medicina personalitzada; Coll - Càncer - Immunoteràpia; Cap - Càncer - Immunoteràpia; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Precision Medicine; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy; DISEASES::Neoplasms::Neoplasms::Neoplasms by Site::Head and Neck Neoplasms::Squamous Cell Carcinoma of Head and Neck; Other subheadings::Other subheadings::/therapy; CHEMICALS AND DRUGS::Biological Factors::Biomarkers::Biomarkers, Tumor; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::medicina de precisión; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia; ENFERMEDADES::neoplasias::neoplasias::neoplasias por localización::neoplasias de cabeza y cuello::carcinoma de células escamosas de cabeza y cuello; Otros calificadores::Otros calificadores::/terapia; COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores::marcadores tumorales
Frontiers Media
Frontiers in Oncology;14
https://doi.org/10.3389/fonc.2024.1473706
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
